With the changing scenario of drug safety and monitoring, stringent and dynamic regulatory requirements, it becomes pivotal for the biopharmaceutical companies to focus not only on the product development but also on the safety monitoring of the products during its phases of clinical trial and post marketing ADR. We at S2M Life Science having a clear understanding of drug safety requirements of global regulators, data management and integration, provide end to end pharmacovigilance support to our clients. Our robust IT infrastructure, technical experts and highly scalable universal capacity enables us to deliver the project in time. We tap into the value of clinical data by harmonizing the process and technology. We seamlessly support our customer in spite of emerging market, higher data volumes and frequently changing regulations. We are powered with 21 CFR (Part 11) and Eudra Vigilance compliant pharmacovigilance data base and Japanese Adverse Drug Event Report (JADER) database for the management of complete adverse events in both pre and post marketing setups. We create and maintain the database on behalf of our client. The database can be assessed by our sponsors and the Qualified person for pharmacovigilance in Europe (QPPV).